Browse MYH4

Summary
SymbolMYH4
Namemyosin, heavy chain 4, skeletal muscle
Aliases MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, myofibril. Note=Thick filaments of the myofibrils.
Domain PF00063 Myosin head (motor domain)
PF02736 Myosin N-terminal SH3-like domain
PF01576 Myosin tail
Function

Muscle contraction.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0006936 muscle contraction
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0014823 response to activity
GO:0030048 actin filament-based movement
GO:0030049 muscle filament sliding
GO:0033275 actin-myosin filament sliding
GO:0042278 purine nucleoside metabolic process
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0070252 actin-mediated cell contraction
GO:1901657 glycosyl compound metabolic process
Molecular Function GO:0000146 microfilament motor activity
GO:0003725 double-stranded RNA binding
GO:0003774 motor activity
GO:0003779 actin binding
GO:0005516 calmodulin binding
GO:0016887 ATPase activity
Cellular Component GO:0005859 muscle myosin complex
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0016460 myosin II complex
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0032982 myosin filament
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
> KEGG and Reactome Pathway
 
KEGG hsa04530 Tight junction
Reactome R-HSA-199991: Membrane Trafficking
R-HSA-1445148: Translocation of GLUT4 to the plasma membrane
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolMYH4
Namemyosin, heavy chain 4, skeletal muscle
Aliases MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYH4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMYH4
Namemyosin, heavy chain 4, skeletal muscle
Aliases MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYH4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYH4
Namemyosin, heavy chain 4, skeletal muscle
Aliases MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYH4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.4080.00813
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.150.505
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.7390.388
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.5870.475
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.9140.527
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0060.997
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1440.747
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1440.828
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.090.599
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYH4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.112.3-1.21
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.115.3-4.20.745
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211728.617.6110.476
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131138.518.220.30.386
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.87.48.40.452
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.215.42.81
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYH4
Namemyosin, heavy chain 4, skeletal muscle
Aliases MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYH4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYH4
Namemyosin, heavy chain 4, skeletal muscle
Aliases MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYH4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYH4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYH4
Namemyosin, heavy chain 4, skeletal muscle
Aliases MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYH4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYH4
Namemyosin, heavy chain 4, skeletal muscle
Aliases MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYH4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYH4
Namemyosin, heavy chain 4, skeletal muscle
Aliases MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYH4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYH4
Namemyosin, heavy chain 4, skeletal muscle
Aliases MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYH4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.